Green Cross Corp - Asset Resilience Ratio
Green Cross Corp (006280) has an Asset Resilience Ratio of 0.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Green Cross Corp for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Green Cross Corp's Asset Resilience Ratio has changed over time. See 006280 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Green Cross Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 006280 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩4.43 Billion | 0.14% |
| Total Liquid Assets | ₩4.43 Billion | 0.14% |
Asset Resilience Insights
- Limited Liquidity: Green Cross Corp maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Green Cross Corp Industry Peers by Asset Resilience Ratio
Compare Green Cross Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Green Cross Corp (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Green Cross Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | ₩1.43 Billion ≈ $970.18K |
₩2.74 Trillion ≈ $1.86 Billion |
-0.17pp |
| 2023-12-31 | 0.22% | ₩5.80 Billion ≈ $3.93 Million |
₩2.64 Trillion ≈ $1.79 Billion |
-0.06pp |
| 2022-12-31 | 0.27% | ₩6.94 Billion ≈ $4.70 Million |
₩2.53 Trillion ≈ $1.71 Billion |
-0.41pp |
| 2021-12-31 | 0.69% | ₩16.88 Billion ≈ $11.44 Million |
₩2.46 Trillion ≈ $1.67 Billion |
-0.39pp |
| 2020-12-31 | 1.08% | ₩23.21 Billion ≈ $15.73 Million |
₩2.15 Trillion ≈ $1.46 Billion |
-1.12pp |
| 2019-12-31 | 2.20% | ₩43.07 Billion ≈ $29.19 Million |
₩1.96 Trillion ≈ $1.33 Billion |
+1.61pp |
| 2018-12-31 | 0.59% | ₩10.11 Billion ≈ $6.85 Million |
₩1.72 Trillion ≈ $1.17 Billion |
+0.57pp |
| 2017-12-31 | 0.02% | ₩268.03 Million ≈ $181.64K |
₩1.70 Trillion ≈ $1.15 Billion |
-3.87pp |
| 2016-12-31 | 3.89% | ₩60.28 Billion ≈ $40.85 Million |
₩1.55 Trillion ≈ $1.05 Billion |
-0.04pp |
| 2015-12-31 | 3.93% | ₩55.58 Billion ≈ $37.67 Million |
₩1.42 Trillion ≈ $959.01 Million |
-0.59pp |
| 2014-12-31 | 4.51% | ₩60.05 Billion ≈ $40.70 Million |
₩1.33 Trillion ≈ $901.56 Million |
+2.75pp |
| 2013-12-31 | 1.76% | ₩19.43 Billion ≈ $13.16 Million |
₩1.10 Trillion ≈ $748.34 Million |
+1.04pp |
| 2012-12-31 | 0.71% | ₩6.82 Billion ≈ $4.62 Million |
₩954.38 Billion ≈ $646.77 Million |
-5.46pp |
| 2011-12-31 | 6.17% | ₩53.09 Billion ≈ $35.98 Million |
₩860.35 Billion ≈ $583.05 Million |
-7.78pp |
| 2010-12-31 | 13.95% | ₩103.44 Billion ≈ $70.10 Million |
₩741.30 Billion ≈ $502.37 Million |
+13.94pp |
| 2006-12-31 | 0.02% | ₩62.39 Million ≈ $42.28K |
₩362.68 Billion ≈ $245.78 Million |
-0.48pp |
| 2005-12-31 | 0.50% | ₩1.48 Billion ≈ $1.00 Million |
₩296.73 Billion ≈ $201.09 Million |
-0.30pp |
| 2004-12-31 | 0.80% | ₩2.00 Billion ≈ $1.35 Million |
₩250.79 Billion ≈ $169.96 Million |
-2.36pp |
| 2003-12-31 | 3.16% | ₩2.78 Billion ≈ $1.89 Million |
₩88.06 Billion ≈ $59.68 Million |
-- |
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more